This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors
Mohamed H Derbala, et al.. Journal for ImmunoTherapy of Cancer, 2026.
DOI: 10.1136/jitc-2025-014768
-
Label-free interferometry platform for drug response profiling of bioprinted tumor organoids at single-organoid resolution
Bowen Wang, et al.. Nature Protocols, 2026.
DOI: 10.1038/s41596-026-01375-5
-
Claude Science, an AI workbench for scientists, is now available
Weekly News Brief: July 20–24, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of July 20–24, 2026.
This week’s brief covers AI for predicting responses to immunotherapy in rare tumors, a new platform profiles drug sensitivity in tumor organoids, and Anthropic launches an AI science workbench with a push into rare disease drug discovery and research.
To learn more about immunotherapy response prediction, read "TME Analysis With Deep Learning Predicts Pembrolizumab Responses in Rare Tumors," or see the source report in the Journal for ImmunoTherapy of Cancer.
For more information on drug response profiling, read "Machine Learning–Powered Platform Enables Single-Organoid Drug Response Profiling," or see the source report in Nature Protocols.
To learn more about Claude Science, read "Anthropic Enters the Health-Care Arena," or see the announcement.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.